铂敏感复发性卵巢癌既往接受PARP抑制剂治疗后奥拉帕利维持再挑战(OReO/ENGOT-ov38):一项IIIb期试验
这项随机双盲多中心IIIb期试验评估既往接受过一种PARP抑制剂治疗的铂敏感复发性卵巢癌患者再次使用奥拉帕利维持治疗的疗效与安全性。BRCA突变队列中位无进展生存期奥拉帕利组4.3个月对比安慰剂组2.8个月(HR 0.57,95%CI 0.37-0.87,P=0.022),非BRCA突变队列为5.3个月对比2.8个月(HR 0.43,95%CI 0.26-0.71,P=0.0023)。
要点
- BRCA突变队列奥拉帕利组中位PFS 4.3个月对比安慰剂组2.8个月,HR 0.57。
- 非BRCA突变队列奥拉帕利组中位PFS 5.3个月对比安慰剂组2.8个月,HR 0.43。
- 两个队列1年PFS率奥拉帕利组分别为19%和14%,安慰剂组均为0%。
核心结论
- 在既往接受过一种PARP抑制剂和至少两线铂类化疗的卵巢癌患者中,奥拉帕利维持再挑战在BRCA突变和非BRCA突变队列中均较安慰剂显著但幅度有限地改善PFS。
研究设计与样本
- 随机、双盲、多中心IIIb期试验(NCT03106987)。
- 入组铂敏感复发性卵巢癌患者,既往接受过一种PARP抑制剂治疗,BRCA突变队列要求既往PARP抑制剂治疗≥18个月(一线化疗后)或≥12个月(二线或后续化疗后),非BRCA突变队列要求≥12个月(一线化疗后)或≥6个月(二线或后续化疗后)。
- 患者末次铂类化疗后处于缓解状态,按2:1随机分配至奥拉帕利片300 mg每日两次维持治疗或安慰剂。
- 主要终点为研究者评估的无进展生存期(PFS)。
- BRCA突变队列奥拉帕利组74例、安慰剂组38例;非BRCA突变队列奥拉帕利组72例、安慰剂组36例;两个队列均>85%患者既往接受≥3线化疗。
主要发现
- BRCA突变队列中位PFS奥拉帕利组4.3个月对比安慰剂组2.8个月(HR 0.57;95%CI 0.37-0.87;P=0.022)。
- BRCA突变队列1年PFS率奥拉帕利组19%对比安慰剂组0%(Kaplan-Meier估计)。
- 非BRCA突变队列中位PFS奥拉帕利组5.3个月对比安慰剂组2.8个月(HR 0.43;95%CI 0.26-0.71;P=0.0023)。
- 非BRCA突变队列1年PFS率奥拉帕利组14%对比安慰剂组0%(Kaplan-Meier估计)。
- 奥拉帕利再挑战未发现新的安全性信号。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge. PATIENTS AND METHODS: This randomized, double-blind, multicenter trial (NCT03106987) enrolled patients with platinum-sensitive relapsed ovarian cancer who had received one prior PARP inhibitor therapy for ≥18 and ≥12 months in the BRCA-mutated and non-BRCA-mutated cohorts, respectively, following first-line chemotherapy or for ≥12 and ≥6 months, respectively, following a second or subsequent line of chemotherapy. Patients were in response following their last platinum-based chemotherapy regimen and were randomized 2 : 1 to maintenance olaparib tablets 300 mg twice daily or placebo. Investigator-assessed progression-free survival (PFS) was the primary endpoint. RESULTS: Seventy four patients in the BRCA-mutated cohort were randomized to olaparib and 38 to placebo, and 72 patients in the non-BRCA-mutated cohort were randomized to olaparib and 36 to placebo; >85% of patients in both cohorts had received ≥3 prior lines of chemotherapy. In the BRCA-mutated cohort, the median PFS was 4.3 months with olaparib versus 2.8 months with placebo [hazard ratio (HR) 0.57; 95% confidence interval (CI) 0.37-0.87; P = 0.022]; 1-year PFS rates were 19% versus 0% (Kaplan-Meier estimates). In the non-BRCA-mutated cohort, median PFS was 5.3 months for olaparib versus 2.8 months for placebo (HR 0.43; 95% CI 0.26-0.71; P = 0.0023); 1-year PFS rates were 14% versus 0% (Kaplan-Meier estimates). No new safety signals were identified with olaparib rechallenge. CONCLUSIONS: In ovarian cancer patients previously treated with one prior PARP inhibitor and at least two lines of platinum-based chemotherapy, maintenance olaparib rechallenge provided a statistically significant, albeit modest, PFS improvement over placebo in both the BRCA-mutated and non-BRCA-mutated cohorts, with a proportion of patients in the maintenance olaparib rechallenge arm of both cohorts remaining progression free at 1 year.
引用
- Pujade-Lauraine E, Selle F, Scambia G, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023. PMID: 37797734. doi:10.1016/j.annonc.2023.09.3110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。